secwatch.observer — SEC 8-K summary
======================================

Issuer:     Semler Scientific, Inc. (—)
CIK:        0001554859
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001554859-24-000013
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Semler Scientific Q1 revenue down 13% to $15.9M; net income up 22% to $6.1M
---------------------------------------------------------------------------

- Revenue of $15.9M, down 13% YoY; fixed-fee software license revenue fell 24% to $7.1M.
- Net income of $6.1M ($0.78 diluted EPS) vs. $5.0M ($0.63) a year ago; operating expenses dropped 25%.
- Cash and equivalents grew to $62.9M from $57.2M at year-end 2023, driven by strong cash generation.
- CEO cites regulatory-driven revenue decline from PAD product; expects re-acceleration if new FDA 510(k) is obtained.
- Three largest customers comprised 45%, 25%, and 11% of Q1 2024 revenue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1554859/000155485924000013/0001554859-24-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1554859/000155485924000013/smlr-20240507x8k.htm
  HTML page:      https://secwatch.observer/filing/0001554859-24-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer